Earlier onset of diabesity-Induced adverse cardiac remodeling in female compared to male mice

Obesity

Volumn 23, Issue 6, 2015, Pages 1166-1177

  Bowden, Marissa A ^a   Tesch, Greg H ^b,c   Julius, Tracey L ^a   Rosli, Sarah ^a   Love, Jane E ^a   Ritchie, Rebecca H ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GLUCOSE; MYOSIN HEAVY CHAIN BETA; PLASMINOGEN ACTIVATOR INHIBITOR 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; GLUCOSE BLOOD LEVEL; REACTIVE OXYGEN METABOLITE; SERPINE1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DB/DB MOUSE; FEMALE; FIBROSIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; SEX DIFFERENCE; WESTERN BLOTTING; ANIMAL; COMPLICATION; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROSIS; HEART; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, OBESE; MODELS, ANIMAL; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; SEX FACTORS; VENTRICULAR REMODELING;

EID: 84929959912     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21072     Document Type: Article

References (40)

1. Roger VL, Go AS, Lloyd-Jones DM, et al., Heart disease and stroke statistics-2012 update a report from the American Heart Association. Circulation 2012; 125: E2-E220.
2. Izadnegahdar M, Norris C, Kaul P, Pilote L, Humphries KH,. Basis for sex-dependent outcomes in acute coronary syndrome. Can J Cardiol 2014; 30: 713-720.
3. Fazal L, Azibani F, Vodovar N, Solal AC, Delcayre C, Samuel J-L,. Effects of biological sex on the pathophysiology of the heart. Br J Pharmacol 2014; 171: 555-566.
4. Laribi S, Aouba A, Nikolaou M, et al., Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail 2012; 14: 234-239.
5. Huynh K, Bernardo BC, McMullen JR, Ritchie RH,. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther 2014; 142: 375-415.
6. Peters SAE, Huxley RR, Woodward M,. Diabetes as risk factor for incident coronary heart disease in women compared with men: A systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014; 57: 1542-1551.
7. Ren J, Kelley RO,. Cardiac health in women with metabolic syndrome: Clinical aspects and pathophysiology. Obesity 2009; 17: 1114-1123.
8. Taegtmeyer H, McNulty P, Young ME,. Adaptation and maladaptation of the heart in diabetes: Part I General concepts. Circulation 2002; 105: 1727-1733.
9. Wu YM, Cazorla O, Labeit D, Labeit S, Granzier H,. Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol 2000; 32: 2151-2161.
10. Asbun J, Villarreal FJ,. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47: 693-700.
11. Huynh K, Kiriazis H, Du XJ, et al., Coenzyme Q(10) attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes. Diabetologia 2012; 55: 1544-1553.
12. Devereux RB, Roman MJ, Paranicas M, et al., Impact of diabetes on cardiac structure and function-The strong heart study. Circulation 2000; 101: 2271-2276.
13. Fang ZY, Prins JB, Marwick TH,. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-567.
14. Dyntar D, Sergeev P, Klisic J, Ambuhl P, Schaub MC, Donath MY,. High glucose alters cardiomyocyte contacts and inhibits myofibrillar formation. J Clin Endocrinol Metab 2006; 91: 1961-1967.
15. Yue P, Arai T, Terashima M, et al., Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. Am JPhysiol Heart Circ Physiol 2007; 292: H2106-H2118.
16. Lim AKH, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH,. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009; 52: 1669-1679.
17. Huynh K, McMullen JR, Julius TL, et al., Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 2010; 59: 1512-1520.
18. Ritchie RH, Love JE, Huynh K, et al., Enhanced phosphoinositide 3-kinase(p110 alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 2012; 55: 3369-3381.
19. Huynh K, Kiriazis H, Du X-J, et al., Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice. Free Radic Biol Med 2013; 60: 307-317.
20. Laskowski A, Woodman OL, Cao AH, et al., Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 2006; 72: 112-123.
21. Ritchie RH, Quinn JM, Cao AH, et al., The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 2007; 42: 1119-1128.
22. Mellor K, Ritchie RH, Meredith G, Woodman OL, Morris MJ, Delbridge LMD,. High-fructose diet elevates myocardial superoxide generation in mice in the absence of cardiac hypertrophy. Nutrition 2010; 26: 842-848.
23. Lin EQ, Irvine JC, Cao AH, et al., Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress cardiomyocyte hypertrophy and superoxide generation. Plos One 2012; 7: e34892.
24. Stampfer MJ, Colditz GA, Willett WC, et al., Postmenopausal estrogen therapy and cardiovascular-disease-10-year follow-up from the Nurses Health Study. N Engl J Med 1991; 325: 756-762.
25. Mendelsohn ME, Karas RH,. Molecular and cellular basis of cardiovascular gender differences. Science 2005; 308: 1583-1587.
26. Kannel WB, Hjortlan. M, Castelli WP,. Role of diabetes in congestive heart failure-Framingham study. Am J Cardiol 1974; 34: 29-34.
27. Boudina S, Abel ED,. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11: 31-39.
28. Boudina S, Sena S, Theobald H, et al., Mitochondrial energetics in the heart in obesity-related diabetics: Direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007; 56: 2457-2466.
29. Del Rio D, Stewart AJ, Pellegrini N,. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005; 15: 316-328.
30. Ahmed FN, Naqvi FN, Shafiq F,. Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. In:, Adeghate E, Saadi H, Adem A, and, Obineche E, eds. Diabetes Mellitus and Its Complications: Molecular Mechanisms, Epidemiology, and Clinical Medicine. Hoboken, NJ: Wiley-Blackwell; 2006, p 481-489.
31. Yang R, Barouch LA,. Leptin signaling and obesity-cardiovascular consequences. Circ Res 2007; 101: 545-559.
32. Bubb KJ, Khambata RS, Ahluwalia A,. Sexual dimorphism in rodent models of hypertension and atherosclerosis. Br J Pharmacol 2012; 167: 298-312.
33. Costa-Goncalves AC, Tank J, Diedrich A, et al., Diabetic hypertensive leptin receptor-deficient db/db mice develop cardioregulatory autonomic dysfunction. Hypertension 2009; 53: 387-392.
34. 2+channel mRNA in streptozotocin-induced diabetic rat heart. J Mol Cell Cardiol 2000; 32: 655-664.
35. Wold LE, Dutta K, Mason MM, et al., Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J Mol Cell Cardiol 2005; 39: 297-307.
36. Karakikes I, Kim M, Hadri L, et al., Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. Plos One 2009; 4: e6474.
37. Sakata S, Lebeche D, Sakata Y, et al., Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther 2006; 13: 987-996.
38. Juhan-Vague I, Alessi MC, Mavri A, Morange PE,. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579.
39. Bai Y, Cui WP, Xin Y, et al., Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol 2013; 57: 82-95.
40. Ghosh AK, Bradham WS, Gleaves LA, et al., Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation 2010; 122: 1200-1209.